Vivet Therapeutics
Vivet Therapeutics - innovative gene therapy treatments for orphan diseasesVivet TherapeuticsVivet Therapeutics

innovative gene therapy treatments for orphan diseases

  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-801 – Wilson’s disease
    • > VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
    • VTX-802 & VTX-803 – PFIC
    • VTX-804 – Citrullinemia Type 1
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet

About us

Board members

Vivet Therapeutics   →  About us   →  Board members

Board members

Chairman of the Board

Eduardo Bravo, MBA

Co-founder & CEO

Jean-Philippe Combal, PharmD, PhD

Pfizer Ventures

Rana Al-Hallaq, PhD

Columbus Venture Partners

Javier García, MBA

Kurma Partners

Vanessa Malier

Roche Venture Fund

Carole Nuechterlein

HealthCap

Mårten Steen, MD, PhD

Novartis Venture Fund

Beat Steffen, MD, MBA

Ysios Capital

Karen Wagner, PhD

  • Our DNA
  • Board members
  • Our leadership
  • Partners

About us

  • Our DNA
  • Board members
  • Our leadership
  • Partners

Pipeline

  • VTX-801 – Wilson’s disease
  • > VTX-801 in Wilson disease – GATEWAY
  • VTX-802 & VTX-803 – PFIC
  • VTX-804 – Citrullinemia Type 1

Patients & Families

  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact